First-of-its-kind, high-throughput and validated sncRNA interrogation platform that provides highly accurate molecular measure of malignancy for detection, risk classification and monitoring of tumors from a single urine specimen without the need for invasive biopsies
| NEW YORK, Jan. 11, 2021 /PRNewswire/ -- The presentation is scheduled for Wednesday, January 13th,2021 and will begin at 3:10pm EDT. A live webcast for conference participants will be available here.
About miR Scientific miR Scientific, LLC, is a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease. Our team developed the miR Scientific Disease Management Platform®, which is comprised of proprietary, non-invasive and highly accurate liquid biopsy urine tests for the detection, classification and monitoring of urological cancers. The Platform is being utilized to commercialize its award-winning miR Sentinel™ Prostate Test. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada and Puerto Rico. Media Contact:
SOURCE miR Scientific, LLC |
View original content to download multimedia:
